

SUPPLEMENTARY TABLES

Table E1. Vision-related function (mean NEI-VFQ-25 composite, NOS-10 composite, and combined NEI-VFQ-25 and NOS-10 composite scores) of RENEW participants at baseline and weeks 24 and 32 (PP population)

Mean (SD) Parameter	Placebo (n = 36)	Opicinumab (n = 33)	All Participants (N = 69)
NEI-VFQ-25 composite score			
Baseline ^a	79.0 (16.6)	75.5 (17.6)	77.3 (17.0)
Week 24	92.9 (6.7)	89.8 (9.9)	91.4 (8.4)
Week 32 ^b	91.9 (7.5)	90.4 (8.8)	91.2 (8.1)
NOS-10 composite score			
Baseline ^c	69.8 (21.2)	63.6 (19.8)	66.9 (20.6)
Week 24 ^b	85.6 (13.3)	80.3 (17.2)	83.1 (15.3)
Week 32 ^d	84.2 (14.2)	79.7 (15.6)	82.1 (14.9)
Combined NEI-VFQ-25 and NOS-10 composite score			
Baseline ^c	77.2 (16.9)	70.4 (18.3)	74.0 (17.8)
Week 24 ^b	90.7 (8.6)	86.8 (12.2)	88.9 (10.6)
Week 32 ^d	89.8 (9.3)	86.7 (11.0)	88.3 (10.2)

NEI-VFQ-25, 25-item National Eye Institute Visual Functioning Questionnaire; NOS-10, 10-item Neuro-Ophthalmic Supplement; PP, per-protocol.

^aPlacebo, n = 35; opicinumab, n = 32; total, N = 67.

^bOpicinumab, n = 32; total, N = 68.

^cPlacebo, n = 34; opicinumab, n = 31; total, N = 65.

^dOpicinumab, n = 31; total, N = 67.